It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
RGEDF’s FA Score shows that 1 FA rating(s) are green whileROMJF’s FA Score has 0 green FA rating(s).
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
ROMJF’s TA Score shows that 4 TA indicator(s) are bullish.
RGEDF (@Pharmaceuticals: Generic) experienced а 0.00% price change this week, while ROMJF (@Pharmaceuticals: Generic) price change was +6.91% for the same time period.
The average weekly price growth across all stocks in the @Pharmaceuticals: Generic industry was +6.26%. For the same industry, the average monthly price growth was +68.76%, and the average quarterly price growth was +80.82%.
A generic drug contains the same chemical substance as a drug that was originally protected by patents. Generic drugs are generally sold at cheaper price points, compared to name-brand pharmaceuticals, after patents for the more expensive drugs lapse. The generic drug industry has created a major market, thanks to the lower pricing. According to the Center for Justice and Democracy at New York Law School, 80 percent of all drugs prescribed are generic, and generic drugs are chosen 94 percent of the time when they are available. But their manufacturers must be able to prove to the FDA that they can be effective substitutes for the original drugs. Some of the major generic drug makers include Zoetis, Inc., Allergan plc and Mylan N.V.
RGEDF | ROMJF | RGEDF / ROMJF | |
Capitalization | 5.69B | 26.4M | 21,553% |
EBITDA | 374B | 3.31M | 11,295,681% |
Gain YTD | 0.000 | 27.433 | - |
P/E Ratio | 7.99 | N/A | - |
Revenue | 878B | 52.2M | 1,681,992% |
Total Cash | 202B | 7.78M | 2,596,067% |
Total Debt | 21.3B | 9.7M | 219,678% |
RGEDF | ROMJF | ||
---|---|---|---|
OUTLOOK RATING 1..100 | 34 | 3 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 3 Undervalued | 45 Fair valued | |
PROFIT vs RISK RATING 1..100 | 74 | 100 | |
SMR RATING 1..100 | 47 | 92 | |
PRICE GROWTH RATING 1..100 | 70 | 38 | |
P/E GROWTH RATING 1..100 | 87 | 100 | |
SEASONALITY SCORE 1..100 | 50 | n/a |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
RGEDF's Valuation (3) in the null industry is somewhat better than the same rating for ROMJF (45). This means that RGEDF’s stock grew somewhat faster than ROMJF’s over the last 12 months.
RGEDF's Profit vs Risk Rating (74) in the null industry is in the same range as ROMJF (100). This means that RGEDF’s stock grew similarly to ROMJF’s over the last 12 months.
RGEDF's SMR Rating (47) in the null industry is somewhat better than the same rating for ROMJF (92). This means that RGEDF’s stock grew somewhat faster than ROMJF’s over the last 12 months.
ROMJF's Price Growth Rating (38) in the null industry is in the same range as RGEDF (70). This means that ROMJF’s stock grew similarly to RGEDF’s over the last 12 months.
RGEDF's P/E Growth Rating (87) in the null industry is in the same range as ROMJF (100). This means that RGEDF’s stock grew similarly to ROMJF’s over the last 12 months.
RGEDF | ROMJF | |
---|---|---|
RSI ODDS (%) | N/A | 3 days ago81% |
Stochastic ODDS (%) | N/A | 3 days ago89% |
Momentum ODDS (%) | N/A | 3 days ago68% |
MACD ODDS (%) | N/A | 3 days ago70% |
TrendWeek ODDS (%) | 3 days ago23% | 3 days ago69% |
TrendMonth ODDS (%) | 3 days ago20% | 3 days ago67% |
Advances ODDS (%) | N/A | 7 days ago71% |
Declines ODDS (%) | N/A | 3 days ago83% |
BollingerBands ODDS (%) | N/A | 3 days ago88% |
Aroon ODDS (%) | N/A | N/A |
1 Day | |||
---|---|---|---|
ETFs / NAME | Price $ | Chg $ | Chg % |
SZNE | 35.02 | 0.14 | +0.39% |
Pacer CFRA-Stovall Eq WghtSeasnlRottnETF | |||
ILDR | 30.38 | 0.01 | +0.03% |
First Trust Innovation Leaders ETF | |||
HIX | 4.32 | N/A | N/A |
Western Asset High Income Fund II | |||
UITB | 46.92 | -0.06 | -0.13% |
VictoryShares Core Intermediate Bond ETF | |||
EMOT | 23.29 | -0.26 | -1.11% |
First Trust S&P 500 Economic Moat ETF |
A.I.dvisor indicates that over the last year, RGEDF has been loosely correlated with PAIOF. These tickers have moved in lockstep 33% of the time. This A.I.-generated data suggests there is some statistical probability that if RGEDF jumps, then PAIOF could also see price increases.
Ticker / NAME | Correlation To RGEDF | 1D Price Change % | ||
---|---|---|---|---|
RGEDF | 100% | N/A | ||
PAIOF - RGEDF | 33% Loosely correlated | N/A | ||
ASRT - RGEDF | 31% Poorly correlated | -0.64% | ||
OILFF - RGEDF | 11% Poorly correlated | +0.26% | ||
OWPC - RGEDF | 4% Poorly correlated | +25.00% | ||
ROMJF - RGEDF | 3% Poorly correlated | -2.03% | ||
More |
A.I.dvisor tells us that ROMJF and PHCUF have been poorly correlated (+13% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that ROMJF and PHCUF's prices will move in lockstep.
Ticker / NAME | Correlation To ROMJF | 1D Price Change % | ||
---|---|---|---|---|
ROMJF | 100% | -2.03% | ||
PHCUF - ROMJF | 13% Poorly correlated | N/A | ||
PCLOF - ROMJF | 8% Poorly correlated | -23.05% | ||
SGIOF - ROMJF | 8% Poorly correlated | +13.16% | ||
SGIOY - ROMJF | 8% Poorly correlated | +0.34% | ||
RSCI - ROMJF | 5% Poorly correlated | N/A | ||
More |